Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Related Keywords

Minnesota ,United States ,Texas ,Chicago ,Illinois ,American ,Robert Martell ,Grzegorz Nowakowski ,James Dentzer ,Duane Mitchell ,Guillermo Garcia Manero ,Head Of Research ,Genentech ,American Society Of Clinical Oncology ,University Of Texas Md Anderson Cancer Center ,Drug Administration ,University Of Florida ,Washington University School Of Medicine ,Nasdaq ,Curis Inc ,Washington University ,Prnewswire Curis Inc ,Department Of Leukemia ,Roche Group ,Division Of Hematology ,Takeaim Lymphoma ,Aim Leukemia ,Takeaim Leukemia ,Clinical Oncology ,Annual Meeting ,Chief Executive Officer ,Aim Lymphoma ,Mayo Clinic Minnesota ,Recommended Phase ,Myelodysplastic Syndromes ,Cancer Center ,Kian Huat Lim ,Washington University School ,Orphan Drug Designation ,Curis ,Nc ,